Skip to main content
. 2022 Nov 8;13:6740. doi: 10.1038/s41467-022-34495-z

Fig. 7. Effects of CD39i combined with commonly used anti-bladder cancer drugs.

Fig. 7

A–C Monotherapy with CD39i or aPD-L1 antibody conspicuously inhibited the tumor growth and improved the mouse prognosis, but the combination therapy with CD39i and aPD-L1 did not show any synergistic effect, n = 10 for each group. D–F The combination strategies, CD39i + CIS and aPD1 + CIS, but not CD39i + aPD1, had a significant synergistic effects on inhibiting tumor growth and improving prognosis, and the combination of CD39i, CIS, and aPD1 had the strongest antitumor efficacy in vivo, n = 10 for each group. Comparisons of tumor growth curves were performed by a two-way ANOVA test followed by Tukey’s multiple comparison test. The log-rank (Mantel–Cox) test was used to compare the survival curves. G CD39i (but not 3 mg/kg cisplatin alone) treatment significantly increased the proportion of tumor infiltrated cDC1 cells, and cisplatin at dose of 3 mg/kg had a synergistic effect with CD39i on increasing the proportion of cDC1 in tumors. cDC1: CD45 + CD11c + MHC II + CD103 + CD11b−. The flow cytometry analyses were repeated at 3 times with 5 samples in each group. Source data are provided as a Source Data file (A, C, D, F). Bar graphs show the mean ± SEM, and P-values <0.05 were considered significant: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.